⏱️ Pipeline Countdown · FDA CDER + Lancet GRAM Data
The Antibiotic Extinction Clock
18 major pharma companies had antibiotic R&D programs in 1990. Only 4 remain. At current rates, functional pipeline exhaustion happens around 2040 — right as resistant infections are projected to kill 1.91 million people per year.
2040Pipeline Exhaustion~14 years away
Current Trajectory — Counting Down
2035Pipeline RecoveryWith intervention
With PASTEUR Act + CARB-X + Subscription Models — Possible by 2035
78%Pharma abandonment rate (1990 → 2020)
1.27MDeaths from resistance in 2019 alone
39MProjected cumulative deaths 2025–2050
<15%Phase I antibiotic success rate (vs 25% oncology)
Choose your depth. The data doesn't change — just the explanation.
We're running out of new antibiotics. Big pharma companies stopped making them because there's no money in it — one company spent $1 billion making a new antibiotic, then went bankrupt because almost no one bought it. By around 2040, we may not have any new drugs to fight resistant bacteria, and those bacteria are already killing over a million people a year.
The antibiotic pipeline is collapsing: 18 major pharma companies had R&D programs in 1990; only 4 do today. The market failure is structural — antibiotics only work if you DON'T use them much (resistance), so there's no revenue model. WHO Critical Priority pathogens (ESKAPE) are already resistant to most existing drugs. The 39M projected deaths 2025-2050 are from the Lancet GRAM 2024 study.
The '~2040 pipeline exhaustion' projection is based on linear extrapolation of two data points: 18 companies (Wellcome Trust, 1990) and 4 companies (Nature, 2020). Intermediate values are interpolated. The O'Neill 10M/year figure is an extreme upper-bound from a 2016 report widely criticized for methodology. Active mitigation: CARB-X ($700M+ committed), PASTEUR Act (pending US Congress), UK antibiotic subscription model (piloted 2022-2024). Pipeline as of WHO 2023: 45 traditional antibiotics in development, but most are modifications of existing classes with limited activity against critical-priority pathogens.
WHO Pipeline data: who.int/publications/i/item/9789240061545. CARB-X portfolio: carb-x.org/portfolio. ClinicalTrials.gov API for antibiotic trials: https://clinicaltrials.gov/api/v2/studies?query.cond=antibiotic+resistant&filter.phase=PHASE3&filter.overallStatus=ACTIVE. FDA CDER antibiotic approvals: accessdata.fda.gov/scripts/cder/daf/.
The Approval Rate Collapse
From 30 antibiotics approved per decade in the 1980s to just 3 total in 2020–2024. That's not a slowdown — it's near-extinction of the development pipeline. The drugs we'll need in 2035 should be in Phase 2 trials now. They're not.
Antibiotic Approvals Per Decade (1980–2024)
FDA CDER records + BMJ Medicine (2022), PubMed PMID 34259076. The 2010s bump from GAIN Act 2012 pulled approvals forward — the underlying trend continued declining.
Pharma Companies in Antibiotic R&D
Wellcome Trust data (1990), Nature Oct 2020 (2020). Linear extrapolation: zero major pharma companies by ~2028. Note: Intermediate values (1995–2015) are interpolated from two documented data points. Actual intermediate values may vary.
Projected AMR Deaths (2025–2050)
Lancet GRAM Project, September 2024 update. At current trajectory: 1.91M direct deaths per year by 2050. For context: tuberculosis causes ~1.25M deaths/year; malaria ~600K/year. AMR overlaps with both.
The Corporate Exodus Timeline
1990
18 major pharma companies in antibiotic R&D. Wellcome Trust documented. Pfizer, Squibb, Eli Lilly, Roche, Bayer, Bristol-Myers, SmithKline Beecham — all active.
2000s
The math became obvious. Antibiotics cure people (short courses). Statins are taken for life. The economics are structural: cure your patient = lose them as a customer.
2011
AstraZeneca exits antibiotic R&D. Pfizer exits shortly after. Sanofi and Allergan follow. The industry titans decide the risk/reward doesn't work.
2019
Achaogen goes bankrupt — $1B spent, plazomicin FDA-approved, $800K in revenue, bankruptcy within months. Same year: Melinta bankrupt. Aradigm bankrupt. The "market failure" becomes undeniable.
2020
Only 4 major pharma companies remain (Nature, Oct 2020). The small biotechs trying to fill the gap lack the capital for Phase 3 trials (~$300-500M) or post-approval marketing.
~2028
Projected: zero major pharma companies in antibiotic R&D. Linear extrapolation of exit rate. Pipeline runs on biotech startups that will need $1B+ and likely go bankrupt.
~2040
Functional pipeline exhaustion. Phase 3 candidates drop below 5. No major drugs in late-stage development. Meanwhile: 1.91M AMR deaths projected per year. We run out of drugs precisely when we need them most.
The Achaogen Paradox
$1B
Spent on R&D 10+ years
→
✓ FDA
Plazomicin approved 2018
→
$800K
Revenue Year 1
→
💀
Bankruptcy 2019
This isn't a bug — it's a feature of a broken market. Antibiotics are the ONE drug class that becomes less effective the more it's used. Market success (high volume) accelerates resistance, destroying the product. Rational actors exit. And they have.
🧬 The Self-Defeating Market
Antibiotics are unique: every successful prescription is one step closer to the drug's obsolescence. Bacteria evolve resistance. So the drug that sells 50 million courses builds resistance 50 million times faster than one that sells 5 million. The economically rational behavior for pharma — minimize market penetration to extend the drug's useful life — directly contradicts how pharmaceutical markets work. No company can survive on limited sales. So they leave. And we're left with no pipeline for the organisms that are evolving resistance right now.
✅ What's Being Done
CARB-X has committed $700M+ to early antibiotic R&D. The PASTEUR Act (pending US Congress) would create 'subscription' payments for critical antibiotics. The UK piloted a subscription model 2022-2024 that guaranteed revenue independent of volume. These are real levers.